Baijin Life Science Holdings (1466) Fundamentals 2026 — Revenue Analysis | SniperIQ

.00 on the HKSE. This SniperIQ fundamentals page covers Baijin Life Science Holdings's valuation, profitability (net margin -42.4%), revenue (HK$89M in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Baijin Life Science Holdings's market cap?

Baijin Life Science Holdings (1466) has a market capitalization of approximately HK$773M, trading at HK

.00 on the HKSE. Market cap moves with the live share price.

What is Baijin Life Science Holdings's P/E ratio?

Baijin Life Science Holdings's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 6.7x. Valuation multiples are best compared with Consumer Cyclical sector peers rather than read in isolation.

How profitable is Baijin Life Science Holdings?

Baijin Life Science Holdings runs a net profit margin of -42.4%, a gross margin of 7.5%, and an operating margin of -37.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Baijin Life Science Holdings generate?

Baijin Life Science Holdings reported revenue of HK$89M for fiscal year 2026, with net income of -HK

8M and earnings per share (EPS) of -0.0449. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Baijin Life Science Holdings pay a dividend?

Baijin Life Science Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Baijin Life Science Holdings financially healthy?

Baijin Life Science Holdings carries a debt-to-equity ratio of 0.15x and a current ratio of 2.97x, with a market beta of -0.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Baijin Life Science Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Baijin Life Science Holdings (1466) the key facts are: market cap HK$773M, revenue HK$89M, 52-week range 0.465-1.7. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Cyclical peers and form your own view.